Wade Sexton, MD

Cancer Focus:
Adrenal Carcinoma, Bladder Cancer, Kidney (Renal Cell) Cancer, Testicular Cancer

Dr. Sexton graduated from Furman University with a Bachelor of Science Degree in Biology. While at Furman, he was a member of the University’s National Championship Football Team. He attended Emory University School of Medicine and then completed his general surgery and urology residency training at the Wake Forest University Baptist Medical Center.  Following residency, Dr. Sexton entered military service and while on active duty with the United States Air Force (USAF), completed a Fellowship in Urologic Oncology at the University of Texas MD Anderson Cancer Center (MDACC).  From 2001-2004, he was stationed at Lackland AFB in San Antonio, Texas, and while on active duty was awarded a Meritorious Service Medal. In 2004, he joined the Moffitt Cancer Center in Tampa, Florida, where he is a Senior Member in the Department of Genitourinary Oncology, and Assistant Chief Medical Officer and Director of Robotic Surgery for Moffitt McKinley Hospital. He was the Director of the Society of Urologic Oncology (SUO) accredited Fellowship Program at Moffitt from 2008-2023 and now serves as the Associate Program Director. Dr. Sexton has held additional leadership positions including Past-President of the Moffitt Medical Staff and Past-President of the Florida Urologic Society. He served on the Board of Directors for the SUO and as Chair of the SUO Fellowship Committee. He is a long-term member of the National Comprehensive Cancer Network’s guideline panel for bladder cancers, and an Assistant Editor for The Journal of Urology. He served the American Board of Urology (ABU) as a writing member of the Examination Committee and continues to serve as an oral examiner for ABU certification. In 2013, he was honored as the MDACC Distinguished Urologic Oncology Alumnus, and in 2019 was recognized as the Moffitt Cancer Center Physician of the Year named in honor of the late Dr. Charles C. Williams, Jr.. Dr. Sexton’s academic and clinical practice is focused on bladder, kidney, and advanced testicular malignancies.  

Education & Training

Fellowship:

• The University of Texas, MD Anderson Cancer Center - Urologic Oncology

Residency:

• Wake Forest University, Winston-Salem, NC - Surgery
• Wake Forest University, Winston-Salem, NC - Urology

Medical School:

• Emory University School of Medicine - MD

Clinical Trial 22193
uTRACT Jelmyto® Registry
Condition: Genitourinary
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Huelster HL, Gould B, Schiftan EA, Camperlengo L, Davaro F, Rose KM, Soupir AC, Jia S, Zheng T, Sexton WJ, Pow-Sang J, Spiess PE, Daniel Grass G, Wang L, Wang X, Vosoughi A, Necchi A, Meeks JJ, Faltas BM, Du P, Li R. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. Eur Urol. 2024 Mar.85(3):283-292. Pubmedid: 37802683.
• Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patanè D, Grass GD, Gilbert SM, Sexton WJ, Bandini M, Moschini M, Briganti A, Montorsi F, Spiess PE, Necchi A. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2024 Jan. Pubmedid: 38184473.
• Jacob JM, Woldu SL, Linehan J, Labbate C, Rose KM, Sexton WJ, Tachibana I, Kaimakliotis H, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipor S, Quek ML, Johnson B, O'Donnell M, Eisner BH, Feldman AS, Murray KS, Matin SF, Lotan Y, Dickstein RJ. First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors. Urol Oncol. 2024 Jan.42(1):20.e17-20.e23. Pubmedid: 37517898.
• Peak T, Tian Y, Patel A, Shaw T, Obermayer A, Laborde J, Kim Y, Johnson J, Stewart P, Fang B, Teer JK, Koomen J, Berglund A, Marchion D, Francis N, Echevarria PR, Dhillon J, Clark N, Chang A, Sexton W, Zemp L, Chahoud J, Wang L, Manley B. Pathogenic Roles for RNASET2 in Clear Cell Renal Cell Carcinoma. Lab Invest. 2024 Feb.104(5):102041. Pubmedid: 38431116.
• Linscott JA, Sexton WJ. Editorial Comment. J Urol. 2024 Apr.211(4):573-574. Pubmedid: 38241201.
• Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2024 Apr.7(2):266-274. Pubmedid: 37442673.
• Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by. Eur Urol Oncol. 2024 Apr.7(2):302-303. Pubmedid: 38000932.
• Davaro F, Davaro E, Rose K, Murthy P, Naidu S, Camperlengo L, Grass GD, Vosoughi A, Jain RK, Zemp L, Yu A, Poch MA, Spiess PE, Gilbert SM, Sexton WJ, Li R. Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma. Urol Oncol. 2023 Sep.41(9):389.e7-389.e13. Pubmedid: 36959058.
• Kaimakliotis HZ, Tachibana I, Woldu S, Labbate C, Jacob J, Murray K, Rose K, Sexton W, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner BH, Matin SF, Lotan Y, Feldman AS. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma. Urol Oncol. 2023 Sep.41(9):387.e1-387.e7. Pubmedid: 37246135.
• Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. Clin Cancer Res. 2023 Oct.29(19):3875-3881. Pubmedid: 37505486.
• Li R, Naidu S, Fan W, Rose K, Huelster H, Grass GD, Vosoughi A, Dhillon J, Kim Y, Gupta S, Jain RK, Zhang J, Zemp L, Yu A, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Sexton WJ. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urol Oncol. 2023 Nov.41(11):457.e17-457.e24. Pubmedid: 37880002.
• Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y, Murray KS. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes. Eur Urol Focus. 2023 Nov.9(6):1052-1058. Pubmedid: 37263827.
• Murthy PB, Sexton WJ. Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?. J Urol. 2023 Nov.210(5):726-727. Pubmedid: 37757487.
• Labbate C, Woldu S, Murray K, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner B, Feldman A, Lotan Y, Matin SF. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. J Urol. 2023 May.209(5):872-881. Pubmedid: 36657029.
• Murthy PB, Naidu S, Davaro F, Spiess PE, Zemp L, Poch M, Jain R, Vosoughi A, Grass GD, Yu A, Sexton WJ, Gilbert SM, Li R. Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension. Curr Oncol. 2023 Mar.30(3):3223-3231. Pubmedid: 36975458. Pmcid: PMC10046994.
• Woldu SL, Labbate C, Murray KS, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipor S, Quek ML, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y. Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes. Urol Oncol. 2023 Mar.41(3):147.e15-147.e21. Pubmedid: 36424224.
• Gore JL, Porten SP, Montgomery JS, Hamilton RJ, Meng MV, Sexton WJ, Psutka SP. Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic. Urol Oncol. 2023 Feb.41(2):65-68. Pubmedid: 34247905. Pmcid: PMC9760099.
• Shapiro DD, Karam JA, Master VA, Sexton WJ, Matin SF, Spiess PE, Abel EJ. Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610. Eur Urol Oncol. 2023 Dec.6(6):638-639. Pubmedid: 37268448.
• Antonelli L, Ardizzone D, Tachibana I, Adra N, Cary C, Hugar L, Sexton WJ, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Cazzaniga W, Nicol D, Gerdtsson A, Tandstad T, Fizazi K, Fankhauser CD. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 Dec.41(34):5296-5305. Pubmedid: 37656935.
• Esdaille AR, Karam JA, Master VA, Spiess PE, Raman JD, Sharma P, Shapiro DD, Das A, Sexton WJ, Zemp L, Patil D, Allen GO, Matin SF, Wood CG, Jason Abel E. Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients. Urology. 2023 Dec.182:168-174. Pubmedid: 37690543.
• Shapiro DD, Karam JA, Master VA, Zemp LW, Sexton WJ, Matin SF, Spiess PE, Jason Abel E. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Uro. Eur Urol. 2023 Aug.84(2):e55-e56. Pubmedid: 37149462.
• Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y, Murray KS. Corrigendum to "Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes" [Eur. Urol. Focus (2023)]. Eur Urol Focus. 2023 Aug. Pubmedid: 37640582.
• Shapiro DD, Karam JA, Zemp L, Master VA, Sexton WJ, Ghasemzadeh A, Schmeusser BN, Davaro F, Peak T, Patil D, Matin S, Spiess PE, Abel EJ. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci. 2023 Apr.50:43-46. Pubmedid: 36861106. Pmcid: PMC9969293.
• Rose KM, Narang G, Rosen G, Labatte C, Dumitrascu C, Campagna J, Yu A, Manley BJ, Spiess PE, Li R, Adibi M, Murray KS, Sexton WJ, Humphreys MR. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study. BJU Int. 2023 Apr.131(4):471-476. Pubmedid: 36285629.
• Dahmen AS, Phuoc VH, Cohen JB, Sexton WJ, Patel SY. Bloodless surgery in urologic oncology: A review of hematologic, anesthetic, and surgical considerations. Urol Oncol. 2023 Apr.41(4):192-203. Pubmedid: 36470804.
• Rose KM, Murray KS, Labbate C, Woldu S, Linehan J, Jacob J, Kaimakliotis H, Dickstein R, Feldman A, Matin SF, Lotan Y, Humphreys MR, Sexton WJ. Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease. Eur Urol Focus. 2023 Apr. Pubmedid: 37059620.
• Meeks JJ, Sexton WJ, Clark PE. Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guérin. J Urol. 2022 Sep.208(3):526-527. Pubmedid: 35549526.
• Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 Oct.40(10):453.e19-453.e26. Pubmedid: 35811208.
• Rose KM, Sexton WJ. Editorial Comment. J Urol. 2022 Oct.208(4):812. Pubmedid: 36082547.
• Eakins RA, Chobrutskiy A, Teer JK, Patel DN, Hsiang M, Huda TI, Zaman S, Sexton WJ, Coppola D, Falasiri S, Blanck G, Chobrutskiy BI. Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity. Mol Immunol. 2022 Oct.150:58-66. Pubmedid: 35987136.
• Chakiryan NH, Gore LR, Reich RR, Dunn RL, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Manley BJ, Sexton WJ, Hollenbeck BK, Gilbert SM. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2022 May.5(5):e2212347. Pubmedid: 35576003. Pmcid: PMC9112069.
• Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Li R, Sexton W, Manley BJ, Gilbert SM. Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder. Urol Oncol. 2022 Mar.40(3):107.e11-107.e17. Pubmedid: 34426068.
• Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A, Baky F, Cazzaniga W, Mayer E, Nicol D, Islamoglu E, de Vergie S, Saoud R, Eggener SE, Nazzani S, Nicolai N, Hugar L, Sexton WJ, Matei DV, De Cobelli O, Cheaib J, Pierorazio PM, Porter J, Hermanns T, Hamilton RJ, Hiester A, Albers P, Clarke N, Mattei A. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol. 2022 Jun.40(6):1505-1512. Pubmedid: 35279732.
• Rose KM, Huelster HL, Roberts EC, Manley BJ, Gilbert SM, Sexton WJ. Contemporary Management of Chylous Ascites after Retroperitoneal Surgery: Development of an Evidence-Based Treatment Algorithm. J Urol. 2022 Jul.208(1):53-61. Pubmedid: 35212572.
• Patel SY, Trona N, Alford B, Laborde JM, Kim Y, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy. Nutr Clin Pract. 2022 Feb.37(1):176-182. Pubmedid: 33900647.
• Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Ne. 2022 Aug.20(8):866-878. Pubmedid: 35948037.
• Huelster HL, Sexton WJ. Real-World Outcomes Driving the Needle toward Simplification of Nonmuscle Invasive Bladder Cancer Risk Stratification. J Urol. 2022 Aug.208(2):239-240. Pubmedid: 35499494.
• Aydin AM, Reich RR, Cao B, Cheriyan SK, Hajiran A, Zemp L, Yu A, Poch MA, Sexton WJ, Li R, Gilbert SM. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urol Oncol. 2022 Apr.40(4):164.e1-164.e7. Pubmedid: 34629281. Pmcid: PMC8960322.
• Chadha J, Adashek JJ, Jim H, Kim Y, Semaan A, Chakiryan NH, Safa H, Hajiran A, Sexton W, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Miss. Clin Genitourin Cancer. 2022 Apr.20(2):e158-e165. Pubmedid: 34974985.
• Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 Oct.206(4):924-932. Pubmedid: 34032503.
• Li R, Jain RK, Sexton WJ. Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6. Eur Urol. 2021 Oct.80(4):e99. Pubmedid: 34364728.
• Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2021 May.4(5):e2111329. Pubmedid: 34032854. Pmcid: PMC8150693.
• Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
• Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
• Hugar LA, Gilbert SM, Sexton WJ, Kamat AM, Li R. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol. 2021 Mar.31(2):160-169. Pubmedid: 33394766.
• Westerman ME, Tabakin AL, Sexton WJ, Chapin BF, Singer EA. Impact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs. Urol Oncol. 2021 Jun.39(6):357-364. Pubmedid: 33160843. Pmcid: PMC7524707.
• Roberts EC, Nealon SW, Dhillon J, Tourtelot JB, McIver B, Sexton WJ. Bilateral testicular adrenal rest tumors in a patient with nonclassical congenital adrenal hyperplasia. IJU Case Rep. 2021 Jul.4(4):243-246. Pubmedid: 34258539. Pmcid: PMC8255286.
• Hajiran A, Azizi M, Aydin AM, Chakiryan NH, Peyton CC, Boulware DC, Manley BJ, Gilbert SM, Sexton WJ. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Ann Surg Oncol. 2021 Jul.28(7):3648-3655. Pubmedid: 33689081. Pmcid: PMC9801512.
• Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan.205(1):100-108. Pubmedid: 32783489. Pmcid: PMC7864376.
• Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Reply By Authors. J Urol. 2021 Jan.205(1):108. Pubmedid: 33095102.
• Valenberg FJPV, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK, Stenzl A, Danella JF, Cline KJ, Williams MB, Montgomery S, David RD, Harris R, Klein EW, Bradford TJ, Wolk FN, Westenfelder KR, Trainer AF, Richardson TA, Egerdie RB, Goldfarb B, Zadra JA, Lu X, Simon IM, Campbell SA, Bates MP, Higuchi RG, Witjes JA. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. Eur Urol Oncol. 2021 Feb.4(1):93-101. Pubmedid: 33004290.
• Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 Apr.204(1):96-106. Pubmedid: 33346915. Pmcid: PMC7944355.
• Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol. 2020 Sep.78(3):387-399. Pubmedid: 32143924. Pmcid: PMC7771323.
• Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 Oct.27(10):882-889. Pubmedid: 32767444.
• Berglund A, Amankwah EK, Kim YC, Spiess PE, Sexton WJ, Manley B, Park HY, Wang L, Chahoud J, Chakrabarti R, Yeo CD, Luu HN, Pietro GD, Parker A, Park JY. Influence of gene expression on survival of clear cell renal cell carcinoma. Cancer Med. 2020 Nov.9(22):8662-8675. Pubmedid: 32986937. Pmcid: PMC7666730.
• Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2020 Mar.18(3):329-354. Pubmedid: 32135513.
• Sexton WJ, Gilbert SM. Focused issue on testicular cancer-forward. Transl Androl Urol. 2020 Jan.9(Suppl 1):S1-S2. Pubmedid: 32055479. Pmcid: PMC6995848.
• Azizi M, Peyton CC, Boulware DC, Gilbert SM, Sexton WJ. Primary tumor size thresholds in stage IA testicular seminoma: Implications for adjuvant therapy after orchiectomy and survival. Urol Oncol. 2020 Jan.38(1):7.e9-7.e18. Pubmedid: 31704139. Pmcid: PMC7771339.
• Cheriyan SK, Nicholson M, Aydin AM, Azizi M, Peyton CC, Sexton WJ, Gilbert SM. Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors. Transl Androl Urol. 2020 Jan.9(Suppl 1):S45-S55. Pubmedid: 32055485. Pmcid: PMC6995850.
• Aydin AM, Zemp L, Cheriyan SK, Sexton WJ, Johnstone PAS. Contemporary management of early stage testicular seminoma. Transl Androl Urol. 2020 Jan.9(Suppl 1):S36-S44. Pubmedid: 32055484. Pmcid: PMC6995845.
• Azizi M, Aydin AM, Cheriyan SK, Peyton CC, Montanarella M, Gilbert SM, Sexton WJ. Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors. Transl Androl Urol. 2020 Jan.9(Suppl 1):S91-S103. Pubmedid: 32055490. Pmcid: PMC6995843.
• Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. 2020 Jan.6(1):104-111. Pubmedid: 30206003. Pmcid: PMC7771285.
• Peyton CC, Hajiran A, Morgan K, Azizi M, Tang D, Chipollini J, Gilbert SM, Poch M, Sexton WJ, Spiess PE. Urinary leak following partial nephrectomy: a contemporary review of 975 cases. Can J Urol. 2020 Feb.27(1):10118-10124. Pubmedid: 32065869.
• Alsina AE, Wind D, Kumar A, Rogers E, Buggs J, Bukkapatnam R, Sexton WJ. Outcomes in Renal Cell Carcinoma With IVC Thrombectomy: A Multiteam Analysis Between an NCI-Designated Cancer Center and a Quaternary Care Teaching Hospital. Am Surg. 2020 Aug.86(8):1005-1009. Pubmedid: 32997953.
• Gilbert SM, Sexton WJ. Optimal Management of High-risk Stage I Nonseminoma Germ Cell Tumor: Active Intervention is the Preferred Option. Eur Urol Focus. 2019 Sep.5(5):704-705. Pubmedid: 31564641.
• Hajiran A, Aydin AM, Cheriyan SK, Sexton WJ. A simplified new-generation renal mass complexity scoring system. Ann Transl Med. 2019 Sep.7(Suppl 6):S223. Pubmedid: 31656802. Pmcid: PMC6789356.
• Peyton CC, Reich RR, Tang D, Alford B, Azizi M, Li R, Sexton WJ, Poch M, Gilbert SM. Identifying and Codifying Complications after Radical Cystectomy: Comparison of Administrative Diagnostic and Procedure Codes, and Clinical Chart Review. J Urol. 2019 Nov.202(5):913-919. Pubmedid: 31219762. Pmcid: PMC7864380.
• Valenberg FJPV, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK, Stenzl A, Danella JF, Shepard B, Cline KJ, Williams MB, Montgomery S, David RD, Harris R, Klein EW, Bradford TJ, Wolk FN, Westenfelder KR, Trainer AF, Richardson TA, Egerdie RB, Goldfarb B, Zadra JA, Ge S, Zhao S, Simon IM, Campbell SA, Rhees B, Bates MP, Higuchi RG, Witjes JA. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. 2019 May.75(5):853-860. Pubmedid: 30553612.
• Park JY, Luu HN, Park HY, Lin HY, Radlein S, Di Pietro G, Yeo CD, Kim SJ, Kang N, Antwi S, Sexton WJ, Spiess PE, Dickinson S, Parker A. Telomere length in peripheral blood leukocytes and risk of renal cell carcinoma. Transl Cancer Res. 2019 Jul.8(Suppl 4):S397-S403. Pubmedid: 35117117. Pmcid: PMC8798989.
• Patel SY, Garcia Getting RE, Alford B, Hussein K, Schaible BJ, Boulware D, Lee JK, Gilbert SM, Powsang JM, Sexton WJ, Spiess PE, Poch MA. Improved Outcomes of Enhanced Recovery After Surgery (ERAS) Protocol for Radical Cystectomy with Addition of a Multidisciplinary Care Process in a US Comprehensive Cancer Care Center. World J Surg. 2018 Sep.42(9):2701-2707. Pubmedid: 29750321. Pmcid: PMC7771278.
• Di Pietro G, Luu HN, Spiess PE, Sexton W, Dickinson S, Parker A, Park JY. Biomarkers and new therapeutic targets in renal cell carcinoma. Eur Rev Med Pharmacol Sci. 2018 Sep.22(18):5874-5891. Pubmedid: 30280768.
• Peyton CC, Azizi M, Chipollini J, Ercole C, Fishman M, Gilbert SM, Juwono T, Lockhart J, Poch M, Pow-Sang JM, Spiess PE, Wiegand L, Sexton WJ. Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience. Clin Genitourin Cancer. 2018 Oct.16(5):e1003-e1013. Pubmedid: 29859736.
• Chipollini J, Alford B, Boulware DC, Forget P, Gilbert SM, Lockhart JL, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA, Patel SY. Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center. BMC Anesthesiol. 2018 Nov.18(1):157. Pubmedid: 30390636. Pmcid: PMC6215353.
• Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol. 2018 Nov.4(11):1535-1542. Pubmedid: 30178038. Pmcid: PMC6248089.
• Wallace E, Higuchi R, Satya M, McCann L, Sin ML, Bridge JA, Wei H, Zhang J, Wong E, Hiar A, Mach KE, Scherr D, Egerdie RB, Ohta S, Sexton WJ, Meng MV, Weizer AZ, Woods M, Jansz GK, Zadra J, Lotan Y, Liao JC. Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection. J Urol. 2018 Mar.199(3):655-662. Pubmedid: 29061538.
• Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018 Jul.7(9):e1476816. Pubmedid: 30228944. Pmcid: PMC6140546.
• Russell CM, Lebastchi AH, Chipollini J, Niemann A, Mehra R, Morgan TM, Miller DC, Palapattu GS, Hafez KS, Sexton WJ, Spiess PE, Weizer AZ. Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. Urology. 2018 Jul.117:95-100. Pubmedid: 29678662.
• Chipollini J, Tang DH, Manimala N, Gilbert SM, Pow-Sang JM, Sexton WJ, Poch MA, Spiess PE. Evaluating the accuracy of intraoperative frozen section during inguinal lymph node dissection in penile cancer. Urol Oncol. 2018 Jan.36(1):14.e1-14.e5. Pubmedid: 29032883.
• Peyton CC, Azizi M, Sexton WJ. Understanding risk and refining surveillance following tumor resection for low grade non-muscle invasive bladder cancer. Transl Androl Urol. 2018 Dec.7(6):987-989. Pubmedid: 30505739. Pmcid: PMC6256040.
• Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, Master VA, Zargar-Shoshtari K, Matin SF, Sexton WJ, Raman JD, Wood CG, Spiess PE. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer. 2018 Apr.16(2):e443-e450. Pubmedid: 29113770. Pmcid: PMC7771342.
• Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2017 Oct.15(10):1240-1267. Pubmedid: 28982750.
• Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival. Urology. 2017 May.103:142-148. Pubmedid: 28011275.
• Leone A, Diorio G, Sexton W, Schell M, Alexandrow M, Fahey JW, Kumar NB. Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach. Oncotarget. 2017 May.8(21):35412-35424. Pubmedid: 28423681. Pmcid: PMC5471065.
• Tong WL, Tu YN, Samy MD, Sexton WJ, Blanck G. Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. Hum Vaccin Immunother. 2017 Mar.13(3):501-506. Pubmedid: 28085544. Pmcid: PMC5360147.
• Samy MD, Tong WL, Yavorski JM, Sexton WJ, Blanck G. T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-β VDJ recombinations associates with a favorable oncologic outcome for bladder cancer. Cancer Immunol Immun. 2017 Mar.66(3):403-410. Pubmedid: 27995306.
• Chipollini J, Tang DH, Hussein K, Patel SY, Garcia-Getting RE, Pow-Sang JM, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center. Urology. 2017 Jul.105:108-112. Pubmedid: 28342928.
• Leone AR, Kidd LC, Diorio GJ, Zargar-Shoshtari K, Sharma P, Sexton WJ, Spiess PE. Bilateral benign renal oncocytomas and the role of renal biopsy: single institution review. BMC Urol. 2017 Jan.17(1):6. Pubmedid: 28081704. Pmcid: PMC5234146.
• Patel S, Hafez O, Sexton WJ, Edwards DA. Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide: A Case Report. A A Case Rep. 2017 Feb.8(4):78-80. Pubmedid: 28195861.
• Tang DH, Nawlo J, Chipollini J, Gilbert SM, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?. Clin Genitourin Cancer. 2017 Dec.15(6):696-703. Pubmedid: 28566202.
• Chipollini J, Tang DH, Gilbert SM, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE. Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer. J Urol. 2017 Dec.198(6):1346-1352. Pubmedid: 28652123.
• Clark NM, Garcia Galindo CA, Patel VK, Parry ML, Stoll RJ, Yavorski JM, Pinkason EP, Johnson EM, Walker CM, Johnson J, Sexton WJ, Coppola D, Blanck G. The human, F-actin-based cytoskeleton as a mutagen sensor. Cancer Cell Int. 2017 Dec.17:121. Pubmedid: 29255378. Pmcid: PMC5727871.
• Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, Powsang JM, Zhang J, Sexton WJ, Spiess PE, Poch MA. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clin Genitourin Cancer. 2017 Aug.15(4):e583-e589. Pubmedid: 28410909. Pmcid: PMC7771283.
• Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 Aug.198(2):281-288. Pubmedid: 28268170.
• Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?. World J Urol. 2017 Apr.35(4):657-663. Pubmedid: 27495912.
• Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Author Reply. Urology. 2017 05.103:148. Pubmedid: 28108090.
• Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Ne. 2016 Oct.14(10):1213-1224. Pubmedid: 27697976. Pmcid: PMC5379654.
• Zargar-Shoshtari K, Sexton WJ, Poch MA. Management of Urethral Recurrences: Urothelial and Nonurothelial. Urol Clin North Am. 2016 Nov.43(4):515-521. Pubmedid: 27717437.
• Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov.34(11):1567-1573. Pubmedid: 27072536.
• Sharma P, Keenan RJ, Sexton WJ. Mass in Solitary Intrathoracic Kidney Within Bochdalek Hernia. Urology. 2016 Nov.97:e15-e16. Pubmedid: 27554626.
• Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May.387(10032):2008-2016. Pubmedid: 26969090. Pmcid: PMC4878938.
• Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol Oncol. 2016 Mar.34(3):122.e1-122.e7. Pubmedid: 26546482. Pmcid: PMC4761468.
• Russell CM, Lue K, Fisher J, Kassouf W, Schwaab T, Sexton WJ, Tanguay S, Psutka SP, Thompson RH, Leibovich BC, Hanzly MI, Spiess PE, Boorjian SA. Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma. BJU Int. 2016 Jun.117(6B):E60-E66. Pubmedid: 26118331.
• Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA. Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. Urology. 2016 Jul.93:130-134. Pubmedid: 27041469.
• Sharma P, Zargar-Shoshtari K, Sexton WJ. Valrubicin in refractory non-muscle invasive bladder cancer. Expert Rev Anticancer Ther. 2016 Jul.15(12):1379-1387. Pubmedid: 26569509.
• Sharma P, Henriksen CH, Zargar-Shoshtari K, Xin R, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy. J Urol. 2016 Jan.195(1):47-52. Pubmedid: 26235376. Pmcid: PMC4924593.
• Markow M, Bui MM, Lin HY, Lloyd M, Sexton WJ, Dhillon J. Evaluation of PAX8 Expression and Its Potential Diagnostic and Prognostic Value in Renal and Extra-Renal Ewing Sarcomas/PNETs. Pathol Oncol Res. 2016 Jan.22(1):115-120. Pubmedid: 26350056.
• Zargar-Shoshtari K, Sverrisson EF, Sharma P, Gupta S, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. Clin Genitourin Cancer. 2016 Feb.14(1):82-88. Pubmedid: 26411593.
• Russell CM, Sharma P, Agarwal G, Fisher JS, Richard GJ, Spiess PE, Pow-Sang JM, Poch MA, Sexton WJ. Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?. Can J Urol. 2016 Feb.23(1):8127-8134. Pubmedid: 26892052.
• Lue K, Russell CM, Fisher J, Kurian T, Agarwal G, Luchey A, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Predictors of Postoperative Complications in Patients Who Undergo Radical Nephrectomy and IVC Thrombectomy: A Large Contemporary Tertiary Center Analysis. Clin Genitourin Cancer. 2016 Feb.14(1):89-95. Pubmedid: 26453395.
• Gill TR, Samy MD, Butler SN, Mauro JA, Sexton WJ, Blanck G. Detection of Productively Rearranged TcR-α V-J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells. Cancer Inform. 2016 Feb.15:23-28. Pubmedid: 26966347. Pmcid: PMC4768948.
• Zargar-Shoshtari K, Ashouri K, Sharma P, Baumgarten A, Sexton WJ, Pow-Sang J, Spiess PE. Nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma among patients with impaired renal function: defining predictors of outcomes. ANZ J Surg. 2016 Dec.86(1-2):44-48. Pubmedid: 26370725.
• Patel S, Hafez O, Sexton WJ, Edwards DA. Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide. A A Case Rep. 2016 Dec. Pubmedid: 27941483.
• Sharma P, Zargar-Shoshtari K, Spiess PE, Sexton WJ, Poch MA. Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy. Urol Ann. 2016 Apr.8(2):151-156. Pubmedid: 27141183. Pmcid: PMC4839230.
• Simon RM, Kim T, Espiritu P, Kurian T, Sexton WJ, Pow-Sang JM, Sverrisson E, Spiess PE. Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy. Int Braz J Urol. 2015 Sep.41(5):911-919. Pubmedid: 26689516. Pmcid: PMC4756967.
• Sharma P, Zargar-Shoshtari K, Caracciolo JT, Richard GJ, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol. 2015 Oct.33(10):1585-1592. Pubmedid: 25552207.
• Luchey AM, Lin HY, Yue B, Agarwal G, Gilbert SM, Lockhart J, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer. J Urol. 2015 Nov.194(5):1220-1225. Pubmedid: 26055823.
• Luchey AM, Agarwal G, Espiritu PN, Lockhart JL, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA. Patient and disease-specific factors and their influence on urinary reconstruction choice at a referral center. World J Urol. 2015 Nov.33(11):1763-1768. Pubmedid: 25774005.
• Zargar-Shoshtari K, Sharma P, Espiritu P, Kurian T, Pow-Sang JM, Mangar D, Sexton WJ, Spiess PE. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. Urol Oncol. 2015 Mar.33(3):112.e23-112.e29. Pubmedid: 25555854.
• Abarzua-Cabezas FG, Sverrisson E, Cruz Rde L, Spiess PE, Haddock P, Sexton WJ. Oncological and functional outcomes of salvage renal surgery following failed primary intervention for renal cell carcinoma. Int Braz J Urol. 2015 Jun.41(1):147-154. Pubmedid: 25928521. Pmcid: PMC4752068.
• Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun.13(3):225-230. Pubmedid: 25544725.
• Emtage JB, Agarwal G, Sexton WJ. Robotic-Assisted Renal Surgery. Cancer Control. 2015 Jul.22(3):291-300. Pubmedid: 26351884.
• Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015 Aug.33(8):339.e17-339.e23. Pubmedid: 26094169.
• Gopman JM, Djajadiningrat RS, Baumgarten AS, Espiritu PN, Horenblas S, Zhu Y, Protzel C, Pow-Sang JM, Kim T, Sexton WJ, Poch MA, Spiess PE. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int. 2015 Aug.116(2):196-201. Pubmedid: 25777366.
• Sharma P, Dhillon J, Agarwal G, Zargar-Shoshtari K, Sexton WJ. Disparities in Interpretation of Primary Testicular Germ Cell Tumor Pathology. Am J Clin Pathol. 2015 Aug.144(2):289-294. Pubmedid: 26185314.
• Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma. Can J Urol. 2015 Aug.22(4):7882-7889. Pubmedid: 26267026.
• Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue B, Sharma P, Spiess PE, Poch MA, Pow Sang J, Sexton WJ. Surveillance Following Nephron-Sparing Surgery: An Assessment of Recurrence Patterns and Surveillance Costs. Urology. 2015 Aug.86(2):321-326. Pubmedid: 26187013.
• Sharma P, Dhillon J, Sexton WJ. Intratubular Germ Cell Neoplasia of the Testis, Bilateral Testicular Cancer, and Aberrant Histologies. Urol Clin North Am. 2015 Aug.42(3):277-285. Pubmedid: 26216815.
• Baumgarten AS, Alhammali E, Hakky TS, Espiritu PN, Pow-Sang JM, Sexton WJ, Lockhart JL, Protzel C, Hakenberg O, Muneer A, Spiess PE. Salvage surgical resection for isolated locally recurrent inguinal lymph node metastasis of penile cancer: international study collaboration. J Urol. 2014 Sep.192(3):760-764. Pubmedid: 24603104.
• Armstrong PA, Back MR, Shames ML, Bailey CJ, Kim T, Lawindy SM, Sexton WJ, Spiess PE. Outcomes after inferior vena cava thrombectomy and reconstruction for advanced renal cell carcinoma with tumor thrombus. J Vasc Surg Venous Lymphat Disord. 2014 Oct.2(4):368-376. Pubmedid: 26993539.
• Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martinw C, Moreno J, Kamat AM. Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. J Urol. 2014 Jun.191(6):1721-1727. Pubmedid: 24342144.
• Espiritu PN, Sverrisson EF, Sexton WJ, Pow-Sang JM, Poch MA, Dhillon J, Spiess PE. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection. Urol Oncol. 2014 Jul.32(5):619-624. Pubmedid: 24495448.
• Rao SR, Moussly S, Pacheco M, Spiess PE, Sexton WJ. Identifying unrecognized collecting system entry and the integrity of repair during open partial nephrectomy: comparison of two techniques. Int Braz J Urol. 2014 Jul. Pubmedid: 24893916.
• Dhillon J, Mohanty SK, Kim T, Sexton WJ, Powsang J, Spiess PE. Spectrum of renal pathology in adult patients with congenital renal anomalies-a series from a tertiary cancer center. Ann Diagn Pathol. 2014 Feb.18(1):14-17. Pubmedid: 24321461.
• Hakky TS, Baumgarten AS, Allen B, Lin HY, Ercole CE, Sexton WJ, Spiess PE. Zonal NePhRO scoring system: a superior renal tumor complexity classification model. Clin Genitourin Cancer. 2014 Feb.12(1):e13-e18. Pubmedid: 24120084.
• Emtage, J.B., Buethe, D.D., Russell, C.M., Sexton, W.J.. Initial experience with robot-assisted retroperitoneal partial nephrectomy for suspected renal cell carcinoma. J Robotic Surg. 2014 Dec.8(4):305-311.
• Russell CM, Buethe DD, Dickinson S, Sexton WJ. Perivascular epithelioid cell tumor (PEComa) of the urinary bladder associated with Xp11 translocation. Ann Clin Lab Sci. 2014 Dec.44(1):91-98. Pubmedid: 24695481.
• Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol. 2014 Aug.66(2):265-272. Pubmedid: 24630419.
• Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE. Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. J Urol. 2014 Aug.192(2):350-356. Pubmedid: 24530987.
• Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA, Biagioli MC. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy. Radiother Oncol. 2014 Apr.111(1):126-131. Pubmedid: 24746567.
• Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2013 May.11(5):594-615. Pubmedid: 23667209. Pmcid: PMC4042432.
• Sexton WJ. Editorial comment. Urology. 2013 Jun.81(6):1244. Pubmedid: 23608665.
• Buethe DD, Sexton WJ, Greene JN, Changcharoen B, Kue-A-Pai P. Infections in oncology: urosepsis due to fluoroquinolone-resistant Escherichia coli after ultrasonographic-guided transrectal implantation of fiducial markers. Cancer Control. 2013 Jul.20(3):233-236. Pubmedid: 23811707.
• Sexton WJ. Editorial comment. J Urology. 2013 Jan.189(1 Suppl):S18. Pubmedid: 23234623.
• Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Ne. 2013 Apr.11(4):446-475. Pubmedid: 23584347.
• Buethe DD, Moussly S, Lin HY, Yue B, Rodriguez AR, Spiess PE, Sexton WJ. Is the R.E.N.A.L. nephrometry scoring system predictive of the functional efficacy of nephron sparing surgery in the solitary kidney?. J Urol. 2012 Sep.188(3):729-735. Pubmedid: 22819418.
• Seifert RP, McNab P, Sexton WJ, Sawczyn KK, Smith P, Coppola D, Bui MM. Rhabdomyomatous differentiation in Wilms tumor pulmonary metastases: a case report and literature review. Ann Clin Lab Sci. 2012 Oct.42(4):409-416. Pubmedid: 23090738.
• Lawindy SM, Kurian T, Kim T, Mangar D, Armstrong PA, Alsina AE, Sheffield C, Sexton WJ, Spiess PE. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. BJU Int. 2012 Oct.110(7):926-939. Pubmedid: 22540179.
• Spiess PE, Kurian T, Lin HY, Rawal B, Kim T, Sexton WJ, Pow-Sang JM. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. BJU Int. 2012 Dec.110(11 Pt B):E470-E474. Pubmedid: 22519938.
• Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM, Dickinson SI, Lin HY, Spiess PE. Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2012 Dec.110(11 Pt B):E475-E480. Pubmedid: 22564727.
• Henderson-Jackson E, Sexton W, Zhang J, Hakam A, Petrovskyy VS, Bui MM, Chuang ST. Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann Clin Lab Sci. 2012.42(1):81-88. Pubmedid: 22371914.
• Kolla SB, Spiess PE, Sexton WJ. Interobserver reliability of the RENAL nephrometry scoring system. Urology. 2011 Sep.78(3):592-594. Pubmedid: 21782219.
• Caso J, Tidwell J, Tsivian M, Sexton WJ. Stapled renal vein with in situ tumor thrombus: a useful intraoperative maneuver to facilitate radical nephrectomy and inferior vena cava thrombectomy. Urology. 2011 Jan.77(1):217-222. Pubmedid: 20472275.
• Buethe DD, Sexton WJ. Bladder cancer: validating the EORTC risk tables in BCG-treated patients. Nat Rev Urol. 2011 Aug.8(9):480-481. Pubmedid: 21844905.
• Sexton WJ, Wiegand LR, Correa JJ, Politis C, Dickinson SI, Kang LC. Bladder cancer: a review of non-muscle invasive disease. Cancer Control. 2010 Oct.17(4):256-268. Pubmedid: 20861813.
• Kolla SB, Ercole C, Spiess PE, Pow-Sang JM, Sexton WJ. Nephron-sparing surgery for pathological stage T3b renal cell carcinoma confined to the renal vein. BJU Int. 2010 Nov.106(10):1494-1498. Pubmedid: 20230378.
• Sexton WJ. Editorial comment. J Urology. 2010 Mar.183(3):969. Pubmedid: 20089275.
• Caso J, Qin D, Sexton WJ. Eosinophilic cystitis following immediate post-resection intravesical instillation of mitomycin-C. Can J Urol. 2010 Jun.17(3):5223-5225. Pubmedid: 20566021.
• Correa JJ, Hakky TS, Spiess PE, Chuang T, Sexton WJ. Robotic-assisted partial cystectomy with en bloc excision of the urachus and the umbilicus for urachal adenocarcinoma. J Robot Surg. 2010 Jan.3(4):235-238. Pubmedid: 27628636.
• Thomas CE, Sexton W, Benson K, Sutphen R, Koomen J. Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol Biomarkers Prev. 2010 Apr.19(4):953-959. Pubmedid: 20332277. Pmcid: PMC2852495.
• Caso J, Seigne J, Back M, Spiess PE, Pow-Sang J, Sexton WJ. Circumferential resection of the inferior vena cava for primary and recurrent malignant tumors. J Urology. 2009 Sep.182(3):887-893. Pubmedid: 19616230.
• Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. J Natl Compr Canc Ne. 2009 Jan.7(1):8-39. Pubmedid: 19176203.
• Moul J, Wu H, Sun L, McLeod D, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen onlyrecurrence of prostate cancer after radical prostatectomy. J Urology. 2008 May.179(5 Suppl):S53-S59. Pubmedid: 18405753.
• Whittemore D, Hick E, Carter M, Moul J, Miranda-Sousa A, Sexton W. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol. 2008 Feb.179(2):516-522. Pubmedid: 18076949.
• Rollison DE, Sexton WJ, Rodriguez AR, Kang LC, Daniel R, Shah KV. Lack of BK virus DNA sequences in most transitional-cell carcinomas of the bladder. Int J Cancer. 2007 Mar.120(6):1248-1251. Pubmedid: 17192899.
• Al-Qudah H, Rodriguez A, Sexton W. Laparoscopic management of kidney cancer: updated review. Cancer Control. 2007 Jul.14(3):218-230. Pubmedid: 17615527.
• Morey A, Evans L, McDonough RC 3rd, Park A, Sexton W, Basler J, SantucciRA, Amling C, O'Reilly K. Evaluation of mechanical bowel preparation methods in urinary diversion surgery. Can J Urol. 2006 Oct.13(5):3250-3254. Pubmedid: 17076946.
• Montie J, Abrahams N, Bahnson R, Eisenberger M, El-Galley R, Herr H, Hudes G, Kuzel T, Lange P, Patterson A, Pollack A, Richie J, Sexton W, Shipley W, Small E, Trump D, Walther P, Wilson T. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc . 2006 Nov.4(10):984-1014. Pubmedid: 17112448.
• Rodriguez A, Kang L, Politis C, Wade M, Sexton W, Miranda-Sousa A, Pow-Sang JM. Delayed metastatic renal carcinoma to prostate. Urology. 2006 Mar.67(3):623.e7-623.10. Pubmedid: 16527593.
• Rodriguez A, Sexton W. Management of locally advanced renal cell carcinoma. Cancer Control. 2006 Jul.13(3):199-210. Pubmedid: 16885916.
• Rodriguez A, Sexton WJ. Management of locally advanced renal cell carcinoma. Cancer Control. 2006 Jul.13(3):199-210. Pubmedid: 16885916.
• Rodriguez A, Burday D, Sexton W, Ahmad N, Pow-Sang J. Urothelial carcinoma in a child. Arch Esp Urol. 2005 Jun.58(5):473-475. Pubmedid: 16078794.
• Baughman S, Sexton W, Glanton C, Dalrymple N, Bishoff J. Computerized tomography guided radio frequency ablation of a renal cell carcinoma within a renal allograft. J Urology. 2004 Oct.172(4 Pt 1):1262-1263. Pubmedid: 15371819.
• Moul J, Wu H, Sun L, McLeod D, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urology. 2004 Mar.171(3):1141-1147. Pubmedid: 14767288.
• Wu H, Sun L, Moul J, Wu H, McLeod D, Amling C, Lance R, Kusuda L, DonahueT, Foley J, Chung A, Sexton W, Soderdahl D. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol. 2004 Mar.171(3):1111-1116. Pubmedid: 14767282.
• Amling C, Riffenburgh R, Sun L, Moul J, Lance R, Kusuda L, Sexton W, Soderdahl D, Donahue T, Foley J, Chung A, McLeod D. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004 Feb.22(3):439-445. Pubmedid: 14691120.
• Moul J, Sun L, Wu H, McLeod D, Amling C, Lance R, Foley J, Sexton W, KusudaL, Chung A, Soderdahl D, Donahue T. Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. Urol Oncol. 2003 Nov.21(6):447-455. Pubmedid: 14693271.
• Carter C, Donahue T, Sun L, Wu H, McLeod D, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackmaan S, Moul J. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003 Nov.21(21):4001-4008. Pubmedid: 14581423.
• Massengill J, Sun L, Moul J, Wu H, McLeod D, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003 May.169(5):1670-1675. Pubmedid: 12686805.
• Baughman S, Sexton W, Bishoff J. Multiple intravesical linear staples identified during surveillance cystoscopy after laparoscopic nephroureterectomy. Urology. 2003 Aug.62(2):351-351. Pubmedid: 12893356.
• Sexton W, Wood C, Kim R, Pisters L. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urology. 2003 Apr.169(4):1353-1356. Pubmedid: 12629359.
• Moul J, Wu H, Sun L, McLeod D, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D, Rich N. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery. 2002 Aug.132(2):213-219. Pubmedid: 12219014.
• Sexton W, Lance R, Reyes A, Pisters P, Tu S, Pisters L. Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience. J Urol. 2001 Aug.166(2):521-525. Pubmedid: 11458058.
• Holmes R, Sexton W, Applewhite J, Kennedy M, Assimos D. Glycolate metabolism by Hep G2 cells. J Am Soc Nephrol. 1999 Nov.10:S345-S347. Pubmedid: 10541260.
• Sexton W, Assimos D. Diagnostic and therapeutic laparoscopy for the adult cryptorchid testicle. Tech Urol. 1999 Mar.5(1):24-28. Pubmedid: 10374791.
• Sexton W, Benedict J, Jarow J. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urology. 1998 Mar.159(3):811-815. Pubmedid: 09474156.
• Sexton WJ, Jarow JP, Benedict JF. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urology. 1998 Mar.159(3):811-815. Pubmedid: 9474156.
• Sexton W, Routh W, McCullough D, Bare R. Hypogastric arterial-ureteral fistula. J Urology. 1998 Jan.159(1):196-197. Pubmedid: 09400472.
• Sexton WJ, Routh WD, McCullough DL, Bare RL. Hypogastric arterial-ureteral fistula. J Urol. 1998 Jan.159(1):196-197. Pubmedid: 9400472.
• Sexton W, Jarow J. Effect of diabetes mellitus upon male reproductive function. Urology. 1997 Apr.49(4):508-513. Pubmedid: 09111618.
• Sexton WJ, Jarow JP. Effect of diabetes mellitus upon male reproductive function. Urology. 1997 Apr.49(4):508-513. Pubmedid: 9111618.
• Poore R, Sexton W, Hart L, Assimos D. Is radiographic evaluation of the chest necessary following flank surgery. J Urology. 1996 Mar.155(3):849-851. Pubmedid: 08583591.
• Poore RE, Sexton WJ, Hart LJ, Assimos DG. Is radiographic evaluation of the chest necessary following flank surgery?. J Urol. 1996 Mar.155(3):849-851. Pubmedid: 8583591.
• Poore RE, Sexton WJ, Hart LJ, Assimos DG. Is radiographic evaluation of the chest necessary following flank surgery?. J Urology. 1996 Mar.155(3):849-851. Pubmedid: 8583591.
• Sverrisson EF, Kim T, Espiritu PN, Sexton WJ, Pow-Sang JM, Dhillon J, Spiess PE. The merits of cytology in the workup for upper tract urothelial carcinoma - a contemporary review of a perplexing issue. Int Braz J Urol. 40(4):493-498. Pubmedid: 25251966.
• Rao SR, Moussly S, Pacheco M, Spiess PE, Sexton WJ. Identifying unrecognized collecting system entry and the integrity of repair during open partial nephrectomy: comparison of two techniques. Int Braz J Urol. 40(5):637-643. Pubmedid: 25498274.
• Sharma P, McCormick BZ, Zargar-Shoshtari K, Sexton WJ. Is surgeon intuition equivalent to models of operative complexity in determining the surgical approach for nephron sparing surgery?. Indian J Urol. 32(2):124-131. Pubmedid: 27127355. Pmcid: PMC4831501.
• Sexton WJ, Spiess PE, Pisters LL, Carpenter S, Madsen LT, Zagone R, Wang X, Troncoso P. Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history?. Int Braz J Urol. 36(5):571-582. Pubmedid: 21044374.